Asia Pacific Alzheimer's Diagnosis and Treatment Market size is expected to cross USD 7,034.3 Million by the end of 2033, growing at a CAGR of 14.6% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of asia pacific alzheimer’s diagnosis and treatment was USD 1,686.9 Million. The growth of the market can be attributed to the growing count of Alzheimer’s patients. There are more than 4 million dementia sufferers in India. Furthermore, the count is further expected to increase and reach nearly 11 million by 2050. There is various variable that imposes the risk of developing dementia. The factors include smoking, obesity, excessive blood sugar, and lack of subject knowledge. Although, the significant rise of 197% in dementia cases is attributed to the growing ageing population.
In addition to these, factors that are believed to fuel the market growth of Asia Pacific Alzheimer’s diagnosis and treatment include rise in the number of clinical trials being carried out on various drugs, and higher approvals of the drugs. For instance, the U.S. Food and Drug Administration has given lecanemab, an experimental anti-amyloid beta (A) protofibril antibody for the treatment of early Alzheimer's disease (AD), Fast Track designation, the drugs were developed by the combined effort of Eisai Co., Ltd. and Biogen Inc. Furthermore, the market growth can also be attributed to the rising efforts to boost the hospital and clinic services for the patients suffering from dementia. BMC-regulated KEM Hospital inaugurated the very first free clinic in Mumbai, India for patient with dementia.
Growth Drivers
Growing Prevalence of Alzheimer’s Disease – Between now and 2050, the number of dementia sufferers in the Asia-Pacific area will triple. More than half of all dementia sufferers globally will reside in the Asia Pacific region by the middle of the century.
Government Initiatives for Alzheimer’s Patients – World Health Organization unveiled an 8-year plan, the “Global Action Plan” for people suffering from dementia. This plan aims to guide member states in creating new strategies and evaluating the pre-existed plans. As of December 2018, 16 plans are available in the Region of Europe (EURO), 5 are in the Region of the Americas (AMRO), 4 are in the Region of the Western Pacific (WPRO), 1 is in the Region of the Eastern Mediterranean (EMRO), and 1 is in the Region of Southeast Asia (SEARO)
Increasing Development of Drugs for Alzheimer’s Disease – For instance, TauRx announced the result from the phase 3 trial of HMTM treatment curated for patients at the early stage of Alzheimer’s. The result indicated that the treatment aided the cognitive improvement and brain atrophy rate achieved similarity with a healthy person.
Growing Geriatric Population – Alzheimer’s disease is the most common reason for the dependency in the elderly population. According to the United Nations, the Asia-Pacific population is aging the fastest of all the regions in the world. Around 60% of the population in the region which is 630 million people are 60 years old or above. However, it is expected that the geriatric population in the region is likely to reach 1.3 billion by 2050.
Rising Investment for the R&D Healthcare Sector – Influx of investment in the healthcare sector is expected to advance the development of Alzheimer’s treatment, diagnostics methods, and dementia care products. According to the Asia-Pacific Trade and Investment Trends 2022/2023, the pharmaceutical industry attracted a higher amount of FDI worth USD 32 billion between 2008-2021, followed by medical devices and healthcare garnering an investment of USD 20 billion and USD 10.8 billion, respectively.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
14.6% |
|
Base Year Market Size (2022) |
USD 1,686.9 Million |
|
Forecast Year Market Size (2033) |
USD 7,034.3 Million |
|
Regional Scope |
|
Diagnosis Method (CT Scan, Magnetic Resonance (MRI), PET Scan, Electroencephalography (EEG), Cerebrospinal Fluid (CSF) Test)
The Asia Pacific Alzheimer’s diagnosis and treatment market is segmented and analyzed for demand and supply by diagnosis method (CT scan, magnetic resonance (MRI), PET scans, electroencephalography (EEG), cerebrospinal fluid (CSF) test, and others. Out of the six types of diagnosis methods, the PET scans segment is estimated to gain the largest market size of USD 898.8 million by the end of 2033 by growing at a CAGR of 9.5% over the projected time frame. Moreover, the segment is to garner a revenue of USD 333.8 million in 2022. Alzheimer's disease's neuropathological signature is brain amyloid (AD). By radiolabeled tracers, it can be detected using in vivo positron emission tomography (PET) imaging. Moreover, PET scanners help in early detection of dementia. Moreover, it aids the better scanning of the brain and improves cognitive neurosciences. The growth of the segment is attributed to the benefits of the PET scans in the detection of dementia. In 15/44 clinical subjects (34%), amyloid PET imaging changed the diagnosis. From around 73% pre-scan to nearly 93% post-scan, the average level of diagnostic confidence increased by around 20%. Furthermore, the growth of the segment can also be credited to the higher number of PRT scanners present in the region. In 2020 there were nearly 550 PET scanners in Japan.
Treatment Provider (Hospitals, Specialty Clinics, Home Care)
The Asia Pacific Alzheimer’s diagnosis and treatment market is also segmented and analyzed for demand and supply by treatment provider hospitals, specialty clinics, and home care. Amongst these three segments, the hospitals segment is expected to garner a market revenue of USD 2761.4 million by the end of 2033 by growing at a CAGR of 14.1% over the forecast period. Additionally, the segment generated a revenue of USD 693.2 million in 2022. Hospitals can provide a better care to the patient suffering from Alzheimer and dementia. In hospital, their condition can be monitored all the time. The segment growth is attributed to the higher admission of dementia affected people in the hospitals. People with dementia currently occupy 1 in every 4 hospital beds. People with dementia frequently have lengthier hospital stays, delayed discharges, and less independence.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment |
|
|
By Diagnosis Method |
|
|
By Treatment Provider |
|
|
By Distribution Channel |
|
The China Alzheimer’s diagnosis and treatment market, amongst the market in all the other regions, is projected to hold the largest market size of USD 2004.8 million by the end of 2033 by growing at a CAGR of 14.8% over the forecast period. Moreover, the market in the region garnered a revenue of USD 474.0 million in 2022. The growth of the market can be attributed majorly to the increasing cases of Alzheimer’s disease along with rising population of elderly in the region. Tens of millions of families in China are dealing with the life-altering burden of caring for relatives who have Alzheimer's disease as the country's population is ageing quickly. Moreover, over the next 20 years, China's old population is expected to increase by over 100 million, which is causing a sharp rise in dementia cases. In China, there are currently thought to be 10 million Alzheimer's sufferers; by 2050, that number is expected to rise to 40 million.
The Japan Alzheimer’s diagnosis and treatment market, amongst the market in all the other regions, is projected to hold the largest market size of USD 1,723.4 million by the end of 2033 by growing at a CAGR of 15.8% over the forecast period. Moreover, the market in the region garnered a revenue of USD 369.4 million in 2022. The market growth in Japan is attributed to increased cases of dementia in Japan. More than 4.6 million people in Japan are affected by dementia. And it is predicted that as the population ages, this number will increase dramatically.
Sysmex Corporation announced the permission to manufacture and market HISCL -Amyloid 1-42 Assay Kit and the HISCL -Amyloid 1-40 Assay Kit in Japan. The Product uses the company's automated immunoassay system HISCL-5000/HISCL-800 (the "HISCL-Series") to measure A levels in the blood and help identify A buildup in the brain, a sign of Alzheimer's disease.
Biogen, Inc. along with Eisai Co., Ltd. Announced that approval of U.S. Food and Drug Administration for ADUHELM has been speed up. Moreover, in order to support access for all eligible patients, particularly for depressed- class of the populations, both the company created a number of programs. These programs seek to aid patients and their families in comprehending the illness, navigating the diagnosis process, obtaining culturally competent care, and managing the cost of treatment.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?